Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/133456
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
Matèries (anglès)
Citació
Citació
TORRES MARTÍ, Antoni, et al. Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. Critical Care. 2018. Vol. 22, num. 1, pags. 343. ISSN 1364-8535. [consulted: 13 of August of 2026]. Available at: https://hdl.handle.net/2445/133456